<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515383</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0271</org_study_id>
    <secondary_id>NCI-2020-07335</secondary_id>
    <secondary_id>2015-0271</secondary_id>
    <nct_id>NCT02515383</nct_id>
  </id_info>
  <brief_title>Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)</brief_title>
  <official_title>Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates how the MD Anderson Symptom Inventory questionnaire modified for use&#xD;
      with adolescents performs in adolescent patients with cancer. Conducting interviews with&#xD;
      adolescents about the MD Anderson Symptom Inventory may help researchers improve the&#xD;
      questionnaire to better understand the symptoms experienced by 13-17 year old patients with&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To examine how the MD Anderson Symptom Inventory (MDASI) modified for use with adolescents&#xD;
      (adolescent version) performs in adolescent patients who have various cancer types, who have&#xD;
      undergone various treatments, and who have varying levels of symptom burden.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the feasibility of various methods for collecting MDASI (adolescent version)&#xD;
      data (for example, paper-and-pencil forms, face-to-face and telephone interviews, electronic&#xD;
      data capture methods such as electronic tablets or automated telephone systems.&#xD;
&#xD;
      II. To evaluate the MDASI (adolescent version) as an estimate of functional status and&#xD;
      quality of life in adolescent cancer patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Part 1: Patients complete the MDASI questionnaire and then complete a cognitive debriefing&#xD;
      interview regarding its comprehensibility, the acceptability of each item, and whether any&#xD;
      important symptoms are missing from the questionnaire.&#xD;
&#xD;
      Part 2: Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1&#xD;
      week after beginning standard of care treatment, patients complete the MDASI questionnaire at&#xD;
      4 additional time points, each 1 week apart. Patients may also complete a cognitive&#xD;
      debriefing interview regarding its comprehensibility, the acceptability of each item, and&#xD;
      whether any important symptoms are missing from the questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of MD Anderson Symptom Inventory (MDASI) modified for use with adolescents (adolescent version)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Data analysis for the cognitive debriefing portion of the study will be qualitative in nature. Construct validity will be determined using factor analysis. Internal consistency reliability will be assessed using Cronbach coefficient alphas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of collection methods</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Patient cognitive debriefing responses about ease of completion based on method and preference for method of completion as well as percentage of successful completions by method during longitudinal assessment in Part 2 will be used to determine the feasibility of the collection methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the MDASI (adolescent version) as an estimate of functional status and quality of life</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The European Quality of Life Five Dimension Questionnaire (EuroQol EQ-5D) and a single-item quality of life question will be compared to MDASI (adolescent version) symptom severity and interference to establish concurrent validity.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Part 1 (MDASI questionnaire, interview)</arm_group_label>
    <description>Patients complete the MDASI questionnaire and then complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (MDASI questionnaires, interview)</arm_group_label>
    <description>Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1 week after beginning standard of care treatment, patients complete the MDASI questionnaire at 4 additional time points, each 1 week apart. Patients may also complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Complete cognitive debriefing interview</description>
    <arm_group_label>Part 1 (MDASI questionnaire, interview)</arm_group_label>
    <arm_group_label>Part 2 (MDASI questionnaires, interview)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Part 1 (MDASI questionnaire, interview)</arm_group_label>
    <arm_group_label>Part 2 (MDASI questionnaires, interview)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete MDASI questionnaire</description>
    <arm_group_label>Part 1 (MDASI questionnaire, interview)</arm_group_label>
    <arm_group_label>Part 2 (MDASI questionnaires, interview)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adolescents diagnosed with cancer being seen at MD Anderson Cancer Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to speak and read English&#xD;
&#xD;
          -  Diagnosis of cancer, confirmed pathologically or clinically&#xD;
&#xD;
          -  Being seen by a healthcare provider at MD Anderson Cancer Center&#xD;
&#xD;
          -  Written assent by subject and written consent by parent/guardian for participation&#xD;
&#xD;
          -  Starting a cycle of chemotherapy, starting radiation therapy, or starting preparative&#xD;
             regimen for stem cell transplantation (Part 2 only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical condition, as determined by the attending physician, that would preclude&#xD;
             participation in the study&#xD;
&#xD;
          -  Diagnosis of active psychosis, developmental delay, or severe cognitive impairment&#xD;
             documented by primary physician in medical record&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Williams</last_name>
    <phone>713-745-3470</phone>
    <email>loriwilliams@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Williams</last_name>
      <phone>713-745-3470</phone>
    </contact>
    <investigator>
      <last_name>Lori Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

